Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4299 - Adjuvant oxaliplatin plus S-1 (SOX) with concurrent radiotherapy versus SOX alone for gastric cancer with D2 lymph node dissection and high risk factors: a randomized phase III trial

Date

09 Sep 2017

Session

Poster display session

Presenters

Xin Wang

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

X. Wang1, Y. Shen1, Q. Li1, M. Qiu1, Z. Li1, J. Liu1, H. Gou1, Y. Yang1, D. Cao1, C. Yi1, D. Luo1, H. Zhu1, Z. Zhou1, S. Tan2, W. Wang3, X. Ye4, X. Su5, F. Xu1, F. Bi1

Author affiliations

  • 1 Department Of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 2 Department Of Oncology, Guizhou Provincial Hospital, Guiyang, Guizhou Province, China,, 550002 - Guiyang/CN
  • 3 Department Of Oncology, Guizhou Cancer Hospital, The Affiliated Cancer Hospital of Guiyang Medical College, Guiyang, China, 550003 - Guiyang/CN
  • 4 Department Of Oncology, Deyang Hospital, Deyang, Sichuan Province, China, 618000 - Deyang/CN
  • 5 Department Of Oncology, Leshan Hospital, Leshan, Sichuan Province, China, 614000 - Leshan/CN
More

Resources

Abstract 4299

Background

The role of adjuvant radiotherapy in patients with radical ressected gastric cancer with D2 lymph node dissection is controversial. Patients with high risk factors including late T stage (T4) and positive lymph nodes (N+) were likely to be benefit from adjuvant concurrent chemoradiotherapy. This trial was designed to compare adjuvant chemoradiotherapy, oxaliplatin plus S-1(SOX) and concurrent radiotherapy, with SOX alone in gastric cancer patients with D2 lymph node dissection and high risk factors.

Trial design

This study is a multiple center randomized phased III controlled trial undertaken by The Western Cooperative Gastrointestinal Oncology Group of China (WCGOG). Patients underwent R0 and D2 gastrectomy and pathologic diagnosed ≥ T4a or positive lymph node (N+) disease per AJCC 7th edition were enrolled in this study. Eligible patients were randomly assigned to receive adjuvant chemotherapy of SOX regimen and concurrent 3D-CRT/IMRT (50.4Gy/28f) or six cycles of SOX alone. Block randomization was done and stratified by disease stage. Primary endpoints are disease-free survival (DFS). Secondary endpoints are overall survival (OS), local control rate (LCR) and toxicity.

Clinical trial identification

ChiCTR-TRC-12002919

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.